Want to see OABI full AI Analyst Report?
Active Clinical Programs & Approved Products
Counts the company’s antibody programs that are in clinical trials or have reached regulatory approval, showing how the discovery platform is turning into potential marketed drugs. Higher numbers signal nearer-term milestone and royalty revenue and provide validation of the platform, while program setbacks or slow trial progress highlight development and timing risk.Active clinical/approved programs have largely plateaued around 32 since late‑2023, but that stability masks improving program quality: Q1 brought two OmnidAb entrants (one to Phase II) and a Phase III progression (Ramantamig), which increases the odds of near‑term milestone receipts and eventual royalties. Management is clearly advancing depth over breadth—fewer net new clinic starts but more late‑stage movement—improving revenue visibility while keeping milestone lumpiness and year‑end cash/runway risk front‑of‑mind.
Date | Active Clinical Programs & Approved Products |
|---|---|
Jun 30, 2026 | 34.00 |
Mar 31, 2026 | 32.00 |
Dec 31, 2025 | 32.00 |
Sep 30, 2025 | 32.00 |
Jun 30, 2025 | 32.00 |
Mar 31, 2025 | 33.00 |
Dec 31, 2024 | 32.00 |
Sep 30, 2024 | 32.00 |
Jun 30, 2024 | 32.00 |
Mar 31, 2024 | 31.00 |